Valentis Files Suit Against ALZA Corp. for Patent Infringement

Apr 10, 2001, 01:00 ET from Valentis, Inc.

    BURLINGAME, Calif., April 10 /PRNewswire/ -- Valentis, Inc. (Nasdaq:   VLTS)
 today confirmed a Bloomberg report that its wholly-owned subsidiary, PolyMASC
 Pharmaceuticals, has filed a lawsuit against ALZA Corporation for patent
 infringement based on ALZA's manufacture and sale of its liposomal products,
 Doxil(R) and Caelyx(R).  Through the lawsuit, PolyMASC is asking the court to
 find that ALZA has infringed PolyMASC's patent.  PolyMASC is seeking monetary
 damages and enhanced damages should the court find that ALZA's infringement
 was willful.
     The lawsuit was filed in the U.S. District Court in Delaware, and alleges
 infringement of U.S. Patent Number 6,132,763, titled "Liposomes."   The
 patent, issued October 17, 2000, is based on early pioneering work by PolyMASC
 inventors and is directed towards PEGylated liposomes (liposomes having
 polyethylene glycol (PEG) chains attached). Doxil(R) and Caelyx(R) are
 PEGylated liposomes encapsulating the drug doxorubicin.  Doxil(R) is approved
 in the U.S. for the treatment of refractory ovarian cancer and AIDS-related
 Kaposi's sarcoma; Caelyx(R) is marketed in Europe and Canada for the treatment
 of advanced ovarian cancer and AIDS-related Kaposi's sarcoma and in Canada for
 breast cancer.
     Liposomes are used to improve the efficacy of small molecule drugs by
 encapsulating them in lipids.  PEGylation of liposomes modifies the
 circulation of the liposomes in the body, enhancing tumor localization and
 reducing non-specific uptake in normal tissues.
     Valentis, Inc. is a leader in the field of biopharmaceutical delivery.
 The Company develops proprietary technologies and applies its preclinical and
 early clinical development expertise to create novel therapeutics.  The
 Company's core technologies include multiple gene delivery and gene expression
 systems and PEGylation technologies designed to improve the safety, efficacy
 and dosing characteristics of genes, proteins, peptides, peptidomimetics,
 antibodies and replicating and non-replicating viruses.
     Together, Valentis and its wholly owned subsidiary PolyMASC
 Pharmaceuticals, currently have corporate collaborations with Roche Holdings,
 Eli Lilly, Glaxo Wellcome, Boehringer Ingelheim, Heska Corporation,
 Transkaryotic Therapies, Onyx Pharmaceuticals, Viragen, and Bayer
 International, and a manufacturing partnership (the pAlliance) with DSM
 Biologics and Qiagen N.V.  Additional information about Valentis can be found
 at www.valentis.com.
     Statements in this press release that are not strictly historical are
 "forward-looking" statements as defined in the Private Securities Litigation
 Reform Act of 1995.  The words "believes," "expects," "intends,"
 "anticipates," variations of such words, and similar expressions identify
 forward-looking statements, but their absence does not mean that the statement
 is not forward-looking.  These statements are not guarantees of future
 performance and are subject to certain risks, uncertainties and assumptions
 that are difficult to predict.  Factors that could affect Valentis' actual
 results include the need for additional capital, the early stage of product
 development, uncertainties related to clinical trials, and uncertainties
 related to patent position.  There can be no assurance that Valentis will be
 able to develop commercially viable gene medicines or PEGylated
 biopharmaceuticals, that any of the company's programs will be partnered with
 pharmaceutical partners, that necessary regulatory approvals will be obtained,
 or that any clinical trial will be successful.  Actual results may differ from
 those projected in forward-looking statements due to risks and uncertainties
 that exist in the companies' operations and business environments.  These are
 described more fully in the Valentis Annual Report on Form 10-K for the period
 ended June 30, 2000 and Quarterly Report on Form 10-Q for the period ended
 December 31, 2000, each as filed with the Securities and Exchange Commission.
 
 

SOURCE Valentis, Inc.
    BURLINGAME, Calif., April 10 /PRNewswire/ -- Valentis, Inc. (Nasdaq:   VLTS)
 today confirmed a Bloomberg report that its wholly-owned subsidiary, PolyMASC
 Pharmaceuticals, has filed a lawsuit against ALZA Corporation for patent
 infringement based on ALZA's manufacture and sale of its liposomal products,
 Doxil(R) and Caelyx(R).  Through the lawsuit, PolyMASC is asking the court to
 find that ALZA has infringed PolyMASC's patent.  PolyMASC is seeking monetary
 damages and enhanced damages should the court find that ALZA's infringement
 was willful.
     The lawsuit was filed in the U.S. District Court in Delaware, and alleges
 infringement of U.S. Patent Number 6,132,763, titled "Liposomes."   The
 patent, issued October 17, 2000, is based on early pioneering work by PolyMASC
 inventors and is directed towards PEGylated liposomes (liposomes having
 polyethylene glycol (PEG) chains attached). Doxil(R) and Caelyx(R) are
 PEGylated liposomes encapsulating the drug doxorubicin.  Doxil(R) is approved
 in the U.S. for the treatment of refractory ovarian cancer and AIDS-related
 Kaposi's sarcoma; Caelyx(R) is marketed in Europe and Canada for the treatment
 of advanced ovarian cancer and AIDS-related Kaposi's sarcoma and in Canada for
 breast cancer.
     Liposomes are used to improve the efficacy of small molecule drugs by
 encapsulating them in lipids.  PEGylation of liposomes modifies the
 circulation of the liposomes in the body, enhancing tumor localization and
 reducing non-specific uptake in normal tissues.
     Valentis, Inc. is a leader in the field of biopharmaceutical delivery.
 The Company develops proprietary technologies and applies its preclinical and
 early clinical development expertise to create novel therapeutics.  The
 Company's core technologies include multiple gene delivery and gene expression
 systems and PEGylation technologies designed to improve the safety, efficacy
 and dosing characteristics of genes, proteins, peptides, peptidomimetics,
 antibodies and replicating and non-replicating viruses.
     Together, Valentis and its wholly owned subsidiary PolyMASC
 Pharmaceuticals, currently have corporate collaborations with Roche Holdings,
 Eli Lilly, Glaxo Wellcome, Boehringer Ingelheim, Heska Corporation,
 Transkaryotic Therapies, Onyx Pharmaceuticals, Viragen, and Bayer
 International, and a manufacturing partnership (the pAlliance) with DSM
 Biologics and Qiagen N.V.  Additional information about Valentis can be found
 at www.valentis.com.
     Statements in this press release that are not strictly historical are
 "forward-looking" statements as defined in the Private Securities Litigation
 Reform Act of 1995.  The words "believes," "expects," "intends,"
 "anticipates," variations of such words, and similar expressions identify
 forward-looking statements, but their absence does not mean that the statement
 is not forward-looking.  These statements are not guarantees of future
 performance and are subject to certain risks, uncertainties and assumptions
 that are difficult to predict.  Factors that could affect Valentis' actual
 results include the need for additional capital, the early stage of product
 development, uncertainties related to clinical trials, and uncertainties
 related to patent position.  There can be no assurance that Valentis will be
 able to develop commercially viable gene medicines or PEGylated
 biopharmaceuticals, that any of the company's programs will be partnered with
 pharmaceutical partners, that necessary regulatory approvals will be obtained,
 or that any clinical trial will be successful.  Actual results may differ from
 those projected in forward-looking statements due to risks and uncertainties
 that exist in the companies' operations and business environments.  These are
 described more fully in the Valentis Annual Report on Form 10-K for the period
 ended June 30, 2000 and Quarterly Report on Form 10-Q for the period ended
 December 31, 2000, each as filed with the Securities and Exchange Commission.
 
 SOURCE  Valentis, Inc.

RELATED LINKS

http://www.megabios.com